Boca Raton FL, www.TheStockWizards.net a Premiere Financial Portal & Investor Relations Firm that brings a wealth of trading resources to Small Cap Investors, has compiled a list of stocks on the OTCBB, and Pink Sheet Markets that have positive technical indicators and may provide continued trading opportunities for investors.
BALTIMORE, Feb. 8Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Lupin's Amlodipine/Benazepril capsules are the AB-rated generic equivalent of Novartis' Lotrel capsules indicated for the treatment
NEW YORK, Feb. 8With the recent election of Senator Scott Brown in Massachusetts resulting in the loss of the Democratic supermajority, the urgency behind broad-based health care reform with the promise of universal coverage for the majority of uninsured Americans has faded dramatically, according to Standard & Poor's Equity Research.
The team at Xtremepicks.com scans the US and Canadian markets looking for microcap companies which show promise and have unique niches and opportunities. Today's news alerts include: Press Release Source: SOHM, Inc. On Monday February 8, 2010, 8:30 am EST.
Boston, MA Smokefree Innotec, Inc.; SOHM, Inc. DayTradersDigest.com is part of Stock Profiler.US, LLC's News Division. Stock Profiler is pleased to introduce Smokefree Innotec, Inc. to the investment community. http://www.youtube.com/watch?v=SGVA7OcZNPU http://www.youtube.com/watch?v=LlTWQnMOoLY Please visit us at www.stockprofiler.us for more d
02/08/10 SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that the Company has entered the multi-vitamin and antioxidant product segment in India and emerging target markets.
02/08/10 SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that is has signed a marketing agreement adding 75 branded generic pharmaceutical products for distribution across India. "Our India based production facility is generating unprecedented grow
PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced that Steven Leventer, Ph.D. has been appointed Vice President, Clinical Research Neuroscience.
02/08/10 Website: www.tevapharm.com www.activebiotech.com/ Contact: Elana Holzman Teva Pharmaceutical Industries Ltd. 972 926-7554 Kevin Mannix Teva North America 591-8912 Goran Forsberg Active Biotech AB +46 46-19 11 54. Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions.
Tranzyme Pharma Announces Approval of Generic Name "Ulimorelin" for TZP-101, its First-in-Class Drug Candidate for the Treatment of Gastrointestinal Dysmotility. Tranzyme Pharma announced that the United States Adopted Name Council has approved the generic name "ulimorelin" for Tranzyme's novel, late-stage, prokinetic agent TZP-101.
Data detailed in 'Statistical assessment of biosimilar products' have been presented. "Patents on the early biological products will soon expire in the next few years. The researchers concluded: "The possibility of using genomic data in evaluation of biosimilar products is also explored."
New research, 'Statistical methods for assessment of biosimilarity using biomarker data,' is the subject of a report. "Food and Drug Administration indicated that the follow-on biologic products can be approved under an abbreviated new drug application if the innovator products are approved under a new drug application.
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application to market its generic version of Novartis' breast cancer treatment Femara Tablets, 2.5 mg. The brand product had annual sales of approximately $556 million in the United Stat
Feb. 5GlaxoSmithKline, one of this region's largest private employers and the foundation of North Carolina's pharmaceutical industry, will continue to shrink. The British company that sells a wide range of products such as the Advair asthma treatment, weight-loss aid alli and Aquafresh toothpaste, is slashing costs as generic rivals hurt sales of
Teva Pharmaceutical Industries Ltd. announced today that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts.
NEW YORK Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, said Friday it is settling several lawsuits related to Medicaid reimbursement for its products, and is setting aside $315 million to cover the settlement and other suits. Teva did not say how much it will pay to resolve the lawsuits and how much will be placed i
Teva Pharmaceutical Industries Ltd. announced that it will be donating over $7 million in medicine to benefit earthquake victims in Haiti. "As a company, Teva was devastated to hear about the earthquake and our hearts and thoughts go out to the country of Haiti," said Shlomo Yanai, Teva's President and Chief Executive Officer.
Aspen Pharmacare, a South African generic pharmaceutical company, has entered into a $1 million agreement with Eli Lilly, a US-based pharmaceutical company, to develop generic versions of the Lilly's tuberculosis medicines, according to Reuters. As part of the agreement, Eli Lilly will transfer its drug production technology to Aspen.
LAKE FOREST, Ill., Feb. 4Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the fourth quarter and full year ended Dec. 31, 2009. "Driven by double-digit revenue and adjusted earnings growth, the fourth quarter concluded a year of transformation for Hospira. Fourth-Quarter 2009 Resul
02/04/10 SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today that Grass Roots Research and Distribution, Inc., a Wall Street leading independent research firm, has initiated unsolicited coverage on SOHM, Inc. with a "BUY" recommendation and a Long-Term
